Stockscreener 앱 받기
3.01
3.61%
0.105
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Is aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis - GlobeNewswire
Logos Global Management LP Adjusts Stake in aTyr Pharma Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 55.1% - MarketBeat
aTyr Pharma Stock Soars to 52-Week High of $3.69 Amidst Robust Gains - Investing.com UK
aTyr Pharma Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.20 loss in 3Q 2023) - Simply Wall St
Atyr Pharma: Q3 Earnings Snapshot - Houston Chronicle
aTyr Pharma Reports Q3 2024 Financial Results - TipRanks
aTyr Pharma Inc Reports Q3 Revenue of $0.353 Million, GAAP EPS L - GuruFocus.com
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
HC Wainwright Reaffirms “Buy” Rating for Atyr PHARMA (NASDAQ:ATYR) - Defense World
aTyr Pharma stock soars to 52-week high, hits $3.6 By Investing.com - Investing.com Canada
aTyr Pharma stock soars to 52-week high, hits $3.6 - Investing.com India
aTyr Pharma keeps stock price target with Buy rating by H.C. Wainwright - Investing.com UK
Atyr PHARMA's (ATYR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Decreases By 21.3% - MarketBeat
aTyr Pharma: The Bull Has Finally Come Out (NASDAQ:ATYR) - Seeking Alpha
High Growth Tech Stocks to Watch in October 2024 - Yahoo Finance
Piper Sandler remains bullish on aTyr Pharma, reiterates Overweight rating By Investing.com - Investing.com UK
It makes sense and dollars to buy Atyr Pharma Inc (ATYR) stock - SETE News
Financial Metrics Check: Atyr Pharma Inc (ATYR)’s Ratios for Trailing Twelve Months - The Dwinnex
Atyr Pharma Inc Inc. (ATYR) Price Performance: The Role of Supply and Demand - The InvestChronicle
Will ATyr Pharma's Efzofitimod Data In Interstitial Lung Disease Trials Make Waves In 2025? - RTTNews
aTyr Pharma stock soars to 52-week high, hits $2.52 - Investing.com India
aTyr Pharma stock soars to 52-week high, hits $2.52 By Investing.com - Investing.com Australia
Atyr Pharma Inc (ATYR) shows promising results - US Post News
Comparing Atyr PHARMA (NASDAQ:ATYR) and Scilex (NASDAQ:SCLX) - Defense World
aTyr Pharma to Present at the LD Micro Main Event XVII in October - Vulcan Advocate
Atyr Pharma Inc (ATYR) rating initates by Wells Fargo - Knox Daily
Atyr PHARMA INC (NASDAQ:ATYR) Sees Large Increase in Short Interest - MarketBeat
Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.8500 - Knox Daily
TSX Smallcap Index (TXTW) QuotePress Release - The Globe and Mail
Analyzing Ratios: Atyr Pharma Inc (ATYR)’s Financial Story Unveiled - The Dwinnex
Atyr Pharma Inc (ATYR) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Atyr Pharma Inc (ATYR)’s stock rises to 1.94 per share - US Post News
With 64% ownership in aTyr Pharma, Inc. (NASDAQ:ATYR), institutional investors have a lot riding on the business - Simply Wall St
aTyr Pharma's efzofitimod showcased at CHEST 2024 - Investing.com
There is no way Atyr Pharma Inc (ATYR) can keep these numbers up - SETE News
aTyr Pharma's efzofitimod showcased at CHEST 2024 By Investing.com - Investing.com UK
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for - GlobeNewswire
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting - StockTitan
Atyr Pharma Inc [ATYR] Investment Guide: What You Need to Know - Knox Daily
3.66%
1.11%
자본화:
|
볼륨(24시간):